{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,8,5]],"date-time":"2024-08-05T17:52:07Z","timestamp":1722880327357},"reference-count":13,"publisher":"Elsevier BV","issue":"4-5","license":[{"start":{"date-parts":[[2015,8,1]],"date-time":"2015-08-01T00:00:00Z","timestamp":1438387200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","bprclinrheum.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Best Practice & Research Clinical Rheumatology"],"published-print":{"date-parts":[[2015,8]]},"DOI":"10.1016\/j.berh.2015.10.001","type":"journal-article","created":{"date-parts":[[2015,12,14]],"date-time":"2015-12-14T21:35:02Z","timestamp":1450128902000},"page":"543-549","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"title":["Treating to target in established rheumatoid arthritis: Challenges and opportunities in an era of novel targeted therapies and biosimilars"],"prefix":"10.1016","volume":"29","author":[{"given":"Thasia G.","family":"Woodworth","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alfons A.","family":"den Broeder","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.berh.2015.10.001_bib1","unstructured":"Smolen JS, Breedveld FC, Burmester GR, et\u00a0al. Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force. Annals of the Rheumatic Diseases."},{"key":"10.1016\/j.berh.2015.10.001_bib2","doi-asserted-by":"crossref","unstructured":"Singh JA, Furst DE, Bharat A, et\u00a0al. 2012 Update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Arthritis Care Res (Hoboken) 64; 625\u2013639.","DOI":"10.1002\/acr.21641"},{"key":"10.1016\/j.berh.2015.10.001_bib3","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1136\/annrheumdis-2013-204573","article-title":"EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs","volume":"73","author":"Smolen","year":"2013","journal-title":"Annals of the Rheumatic Diseases"},{"key":"10.1016\/j.berh.2015.10.001_bib4","doi-asserted-by":"crossref","unstructured":"Pope JE, Haraoui B, Rampakakis E, et\u00a0al Treating to a target in established active rheumatoid arthritis patients receiving a tumor necrosis factor inhibitor: results from a real-world cluster-randomized adalimumab trial. Arthritis Care Res (Hoboken) 65; 1401\u20131409.","DOI":"10.1002\/acr.22010"},{"key":"10.1016\/j.berh.2015.10.001_bib5","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1136\/annrheumdis-2015-eular.2521","article-title":"Conventional DMARD therapy and improvement of disease activity in a cohort of rheumatoid arthritis patients treated under treat to target recommendations","volume":"74","author":"Santos-Moreno","year":"2015","journal-title":"Annals of the Rheumatic Diseases"},{"key":"10.1016\/j.berh.2015.10.001_bib6","doi-asserted-by":"crossref","unstructured":"Gaujoux-Viala C, Nam J, Ramiro S et\u00a0al. Efficacy of conventional synthetic disease-modifying antirheumatic drugs, glucocorticoids and tofacitinib: a systematic literature review informing the 2013 update of the EULAR recommendations for management of rheumatoid arthritis. Annals of the Rheumatic Diseases 73; 510\u2013515.","DOI":"10.1136\/annrheumdis-2013-204588"},{"key":"10.1016\/j.berh.2015.10.001_bib7","doi-asserted-by":"crossref","unstructured":"Nam JL, Ramiro S, Gaujoux-Viala C, et\u00a0al. Efficacy of biological disease-modifying antirheumatic drugs: a systematic literature review informing the 2013 update of the EULAR recommendations for the management of rheumatoid arthritis. Annals of the Rheumatic Diseases 73; 516\u2013528.","DOI":"10.1136\/annrheumdis-2013-204577"},{"key":"10.1016\/j.berh.2015.10.001_bib8","doi-asserted-by":"crossref","unstructured":"Anderson JK, Zimmerman L, Caplan L, et\u00a0al Measures of rheumatoid arthritis disease activity: patient (PtGA) and Provider (PrGA) global assessment of disease activity, disease activity score (DAS) and disease activity score with 28-Joint counts (DAS28), simplified disease activity Index (SDAI), clinical disease activity Index (CDAI), patient activity score (PAS) and patient activity score-II (PASII), routine assessment of patient Index data (RAPID), rheumatoid arthritis disease activity Index (RADAI) and rheumatoid arthritis disease activity Index-5 (RADAI-5), chronic arthritis Systemic Index (CASI), patient-based disease activity score with ESR (PDAS1) and patient-based disease activity score without ESR (PDAS2), and Mean Overall Index for rheumatoid arthritis (MOI-RA). Arthritis Care Res (Hoboken ) 63 Suppl 11; S14\u2013S36.","DOI":"10.1002\/acr.20621"},{"key":"10.1016\/j.berh.2015.10.001_bib9","doi-asserted-by":"crossref","unstructured":"Ward MM, Guthrie LC, Alba MI Clinically important changes in individual and composite measures of rheumatoid arthritis activity: thresholds applicable in clinical trials. Annals of the Rheumatic Diseases 74; 1691\u20131696.","DOI":"10.1136\/annrheumdis-2013-205079"},{"key":"10.1016\/j.berh.2015.10.001_bib10","doi-asserted-by":"crossref","unstructured":"Anderson J, Caplan L, Yazdany J et\u00a0al. Rheumatoid arthritis disease activity measures: American College of Rheumatology recommendations for use in clinical practice. Arthritis Care Res (Hoboken) 64; 640\u2013647.","DOI":"10.1002\/acr.21649"},{"key":"10.1016\/j.berh.2015.10.001_bib11","doi-asserted-by":"crossref","unstructured":"Fleischmann R, van der Heijde D, Koenig AS, et\u00a0al. How much does Disease Activity Score in 28 joints ESR and CRP calculations underestimate disease activity compared with the Simplified Disease Activity Index? Annals of the Rheumatic Diseases 74; 1132\u20131137.","DOI":"10.1136\/annrheumdis-2013-204920"},{"key":"10.1016\/j.berh.2015.10.001_bib12","unstructured":"Berthelot JM RAPID3? Aptly named! Clin Exp Rheumatol 32; S-4."},{"key":"10.1016\/j.berh.2015.10.001_bib13","first-page":"136","article-title":"Assessing remission in rheumatoid arthritis on the basis of patient reported outcomes\u2013advantages of using RAPID3\/MDHAQ in routine care","volume":"72","author":"Castrejon","year":"2013","journal-title":"Bulletin Hospital for Joint Diseases"}],"container-title":["Best Practice & Research Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521694215001047?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521694215001047?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,9,2]],"date-time":"2019-09-02T09:52:46Z","timestamp":1567417966000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521694215001047"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,8]]},"references-count":13,"journal-issue":{"issue":"4-5","published-print":{"date-parts":[[2015,8]]}},"alternative-id":["S1521694215001047"],"URL":"https:\/\/doi.org\/10.1016\/j.berh.2015.10.001","relation":{},"ISSN":["1521-6942"],"issn-type":[{"value":"1521-6942","type":"print"}],"subject":[],"published":{"date-parts":[[2015,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Treating to target in established rheumatoid arthritis: Challenges and opportunities in an era of novel targeted therapies and biosimilars","name":"articletitle","label":"Article Title"},{"value":"Best Practice & Research Clinical Rheumatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.berh.2015.10.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}